plerixafor 為hematopoietic stem cell mobilizer，與顆粒球群落形成刺激因子(G-CSF)並用，刺激造血幹細胞由骨髓釋放到周邊，供收集以施行自體移植。適用於要做自體移植的non-Hodgskin's lymphoma或是multiple myeloma的病患。

Plerixafor 

- Prevents the binding of stromal cell-derived factor-1α (SDF-1α) to the CXCR4 chemokine receptor. 

- Disrupts interaction between SDF-1α and its receptor and interferes with retention of hematopoietic stem cells in bone marrow matrix. 

-> Subsequently, increased numbers of CD34+ hematopoietic progenitor cells are mobilized or released from bone marrow, resulting in peripheral leukocytosis. 

=> Mobilized CD34+ cells were then collected by apheresis and used as a stem-cell infusion to promote engraftment following high-dose chemotherapy associated with autologous stem-cell transplantation

造血幹細胞驅動劑 plerixafor ( Mozobil®，總動原注射劑 )，是一澄清無色至淡 黃色注射液，可抑制造血幹細胞或腫瘤細胞之 CXC chemokine receptor 4 ( CXCR4 )，阻斷 CXCR4 與骨髓 內骨基質細胞之 stromal cell-derived factor-1-alpha ( SDF-1α ) 連結，使白血球細胞增生及周邊血造血 先驅細胞增加。所以 plerixafor 搭配 G-CSF 可協同 驅動出足夠帶有 CD34+抗原的造血幹細胞，以供移 植之用。由於被驅動的造血幹細胞表面有 CD34+ 抗原，可用此標誌定量及計數造血幹細胞，也可降 低微量癌細胞污染可能性。